TP-317 for Treatment of IBD
Safe, first-in-class, oral therapy for induction and maintenance of remission in patients that fail first-line therapy prior to
escalation to biologics.
TP-317 is a new molecular entity that delivers Resolvin E1 (RvE1), a naturally-occurring lipid mediator that resolves inflammation and promotes wound healing. In preclinical colitis studies, both TP-317 and RvE1 have been shown to improve clinical, histopathological, and immunological markers of disease activity. However, RvE1 itself has major shortcomings including very poor stability and lack of IP. Enabled by our HEALER technology, TP-317 overcomes these deficits, with prospects for long-term patent exclusivity to 2041. Thetis was recently awarded a $2.3 million Fast Track NIH grant to develop TP-317 for ulcerative colitis (UC).